As BioMarin turns to commercialization of Roctavian, we will likely hear more about how warranties could help gene therapies overcome payer reimbursement hurdles.
Whenever a policy as far-reaching as eliminating continuous enrollment in Medicaid is considered it would seem prudent to weigh the costs of foregone alternatives.
Declining a debate with an anti-vaccine crusader is understandable. It would amplify and in the eyes of many viewers legitimize Kennedy as somehow an equal adversary.
Eroxon’s approval as an ED product is part of trend in which OTC availability is increasing in therapeutic classes which were formerly off limits to OTC drugs.
Merck seeks a fair drug price in lawsuit against the IRA, but so does Medicare. Neither price Is fair. Merck and Medicare use notions of fairness untethered to value.
Merck seeks a fair drug price in lawsuit against the IRA, but so does Medicare. Neither price Is fair. Merck and Medicare use notions of fairness untethered to value.
The U.S. market for new obesity drugs is much larger than Europe’s. Substantially lower obesity prevalence in Europe is an obvious reason. But there are many others.
For several years, Europe has been moving in a different direction from the U.S., as Europeans exercise greater restraint when treating children with gender dysphoria.
Royal Netherlands Academy of Arts and Sciences publishes report on climate change’s impact on health, warning of dire consequences if we don’t act to curb global warming.
Data from the Netherlands suggest that among people ages 25 and up, memory and concentration problems have risen by 24% since the beginning of the Covid-19 pandemic.